Clinical Study of XNW5004 Combined With CHOP/CHOEP in the Treatment of Untreated Peripheral T-Cell Lymphoma

Inclusion Criteria: * Age 18 to 75 years (inclusive); both genders are eligible. * Pathologically confirmed peripheral T-cell lymphoma (PTCL). * No prior systemic anti-PTCL therapy. * At least one measurable lesion as the basis for evaluation: nodal lesions with a long diameter \> 1.5 cm; extranodal lesions with a long diameter \> 1.0 cm. * Life expectancy of at least 12 weeks. * ECOG performance status score of 0-1. * Vital organ function reserves meet the following requirements: * Hematopoietic function: * White blood cell count \>= 3.5 x 10\^9/L (no G-CSF administration within 1 week before the screening blood test, and no long-acting leukocyte-elevating agent administration within 2 weeks) * Platelet count \>= 75 x 10\^9/L (no platelet transfusion or TPO receptor agonist administration within 1 week before the screening blood test) * Hemoglobin \>= 80 g/L (no red blood cell transfusion or EPO administration within 1 week before the screening blood test) * Hepatic function: serum total bilirubin \<= 1.5 x ULN (\<= 3 x ULN for Gilbert's syndrome), and ALT and AST \<= 2.5 x ULN; for subjects with liver infiltration, ALT/AST \<= 5 x ULN; for subjects with liver and/or bone infiltration, alkaline phosphatase \<= 5 x ULN * Renal function: serum creatinine \<= 1.5 x ULN or estimated creatinine clearance \>= 60 mL/min according to the Cockcroft-Gault formula * Left ventricular ejection fraction (LVEF) \>= 50% * International normalized ratio (INR) \<= 1.5 x ULN, or prothrombin t…